Retrospective Analysis for Patients With Hemophagocytosis in Bone Marrow

Hemophagocytosis Clinical Trial

Official title:

Comparison of Malignant and Non-malignant Disorders Associated Bone Marrow Hemophagocytosis: A Single Center Experience

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02401932
• Other study ID #: 2015-02-013
• Status: Completed
• Phase: N/A
• First received: March 9, 2015
• Last updated: November 8, 2015
• Start date: January 2014
• Est. completion date: September 2015

Study information

• Verified date: November 2015
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Comparison of malignant and non-malignant disorders associated bone marrow hemophagocytosis.

Description:

This is a retrospective study comparing malignant and non-malignant disorders associated bone marrow hemophagocytosis. The medical record of patients who had documented evidences of hemophagocytosis in bone marrow are reviewed. The clinical and biological characteristics are compared according to the underlying disorders of hemophagocytosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• patients who had evidence of hemophagocytic histiocytosis in bone marrow aspiration and biopsy

Exclusion Criteria:

• patients who did not evidence of hemophagocytic histiocytosis in bone marrow aspiration and biopsy

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Hemophagocytosis

Intervention

Other:
• Hemophagocytosis
Best supportive care and immunosuppressive treatments

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival		12 Months	No